Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells

Molecular Cancer Therapeutics

Volumn 4, Issue 8, 2005, Pages 1268-1276

  Jordheim, Lars Petter ^a   Guittet, Olivier ^b   Lepoivre, Michel ^b   Galmarini, Carlos M ^a   Dumontet, Charles ^a  

^a Institut Nat ional de la Santé et de la Recherche Médicale   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4,5 DIHYDROXY 3 HYDROXYMETHYL 2 CYCLOPENTEN 1 YL)CYTOSINE; 3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; 3,4 DIHYDROXYBENZOHYDROXAMIC ACID; 3,4,5 TRIHYDROXYBENZOHYDROXAMIDOXIME; ANTINEOPLASTIC AGENT; CISPLATIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GENOMIC DNA; HYDROXYUREA; PROTEIN SUBUNIT; RIBONUCLEOTIDE REDUCTASE; UNCLASSIFIED DRUG;

ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CARCINOMA CELL; CELL STRAIN; CLINICAL OBSERVATION; CONTROLLED STUDY; CROSS RESISTANCE; DNA MODIFICATION; DRUG EXPOSURE; ENZYME ACTIVITY; ENZYME MECHANISM; GENE DOSAGE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; PROTEIN SUBUNITS; RIBONUCLEOTIDE REDUCTASES; UP-REGULATION;

EID: 23844466231     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0121     Document Type: Article

References (40)

1. Vansteenkiste JF, Vandebroek JE, Nackaerts KL, et al. Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann Oncol 2001;12:1221-30.
2. Markman M, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J. Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol 2003;90:593-6.
3. Heinemann V. Role of gemcitabine in the treatment of advanced and metastatic breast cancer. Oncology 2003;64:191-206.
4. Hussain SA, James ND. The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol 2003;4:489-97.
5. Jordheim L, Galmarini CM, Dumontet C. Drug resistance to cytotoxic nucleoside analogues. Curr Drug Targets 2003;4:443-60.
6. Bouffard DY, Laliberte J, Momparler RL. Kinetic studies on 2′,2′-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol 1993;45: 1857-61.
7. Krishnan P, Fu Q, Lam W, Liou JY, Dutschman G, Chang YC. Phosphorylation of pyrimidine deoxynucleoside analog diphosphates: selective phosphorylation of L-nucleoside analog diphosphates by 3-phosphoglycerate kinase. J Biol Chem 2002;277:5453-9.
8. Liou JY, Dutschman GE, Lam W, Jiang Z, Chang YC. Characterization of human UMP/CMP kinase and its phosphorylation of D- and L-form deoxycytidine analogue monophosphates. Cancer Res 2002;62: 1624-31.
9. Heinemann V, Xu YZ, Chubb S, at al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 1990;38:567-72.
10. Kim MY, Ives DH. Human deoxycytidine kinase: kinetic mechanism and end product regulation. Biochemistry 1989;28:9043-7.
11. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991;51: 6110-7.
12. Heinemann V, Schulz L, Issels RD, Plunkett W. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol 1995;22:11-8.
13. Ruiz van Haperen VW, Veerman G, Vermorken JB, Peters GJ. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol 1993;46:762-6.
14. Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 2002;5: 19-33.
15. Mackey J, Baldwin SA, Young JD, Cass CE. Nucleoside transport and its significance for anticancer drug resistance. Drug Resist Updat 1998; 1:310-24.
16. Mackey JR, Mani RS, Selner M, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998;58:4349-57.
17. Galmarini CM, Clarke ML, Santos CL, et al. Sensitization of ara-C-resistant lymphoma cells by a pronucleotide analogue. Int J Cancer 2003; 107:149-54.
18. Jordheim LP, Cros E, Gouy MH, et al. Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug. Clin Cancer Res 2004; 10: 5614-21.
19. Dumontet C, Fabianowska-Majewska K, Mantincic D, et al. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol 1999;106:78-85.
20. Heinemann V, Xu YZ, Chubb S, et al. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res 1992;52:533-9.
21. Mazzon C, Rampazzo C, Scaini MC, et al. Cytosolic and mitochondrial deoxyribonucleotidases: activity with substrate analogs, inhibitors and implications for therapy. Biochem Pharmacol 2003;66:471-9.
22. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004;64:3761-6.
23. Hurta RA, Wright JA. Amplification of the genes for both components of ribonucleotide reductase in hydroxyurea resistant mammalian cells. Biochem Biophys Res Commun 1990;167:258-64.
24. Wright JA, Alam TG, McClarty GA, Tagger AY, Thelander L. Altered expression of ribonucleotide reductase and role of M2 gene amplification in hydroxyurea-resistant hamster, mouse, rat, and human cell lines. Somat Cell Mol Genet 1987;13:155-65.
25. Yen Y, Grill SP, Dutschman GE, Chang CN, Zhou BS, Cheng YC. Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine. Cancer Res 1994;54:3686-91.
26. Goan YG, Zhou B, Hu E, Mi S, Yen Y. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 1999;59: 4204-7.
27. Mansson E, Flordal E, Liliemark J, et al. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem Pharmacol 2003;65:237-47.
28. Rosell R, Denenberg KD, Alberola V, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004;10: 1318-25.
29. Galmarini CM, Thomas X, Calvo F, et al. Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res 2002;26:621-9.
30. Lepoivre M, Chenais B, Yapo A, Lemaire G, Thelander L, Tenu JP. Alterations of ribonucleotide reductase activity following induction of the nitrite-generating pathway in adenocarcinoma cells. J Biol Chem 1990; 265:14143-9.
31. Guittet O, Hakansson P, Voevodskaya N, et al. Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J Biol Chem 2001;276: 40647-51.
32. Zhou BS, Hsu NY, Pan BC, Doroshow JH, Yen Y. Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells. Cancer Res 1995;55: 1328-33.
33. Mann GJ, Musgrove EA, Fox RM, Thelander L. Ribonucleotide reductase M1 subunit in cellular proliferation, quiescence, and differentiation. Cancer Res 1988;48:5151-6.
34. Kuo ML, Kinsella TJ. Expression of ribonucleotide reductase after ionizing radiation in human cervical carcinoma cells. Cancer Res 1998; 58:2245-52.
35. 1 phase restriction point block. J Clin Invest 1991;87-519-27.
36. Rubin EH, Cory JG. Differential turnover of the subunits of ribonucleotide reductase in synchronized leukemia L1210 cells. Cancer Res 1986;46:6165-8.
37. Engstrom Y, Eriksson S, Jildevik I, Skog S, Thelander L, Tribukait B. Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits. J Biol Chem 1985;260: 9114-6.
38. Chen FY, Amara FM, Wright JA. Defining a novel ribonucleotide reductase r1 mRNA cis element that binds to an unique cytoplasmic transacting protein. Nucleic Acids Res 1994;22:4796-7.
39. Schuetz JD, Connelly MC, Sun D, et al. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 1999;5:1048-51.
40. Zhou B, Mo X, Liu X, Qiu W, Yen Y. Human ribonucleotide reductase M2 subunit gene amplification and transcriptional regulation in a homogeneous staining chromosome region responsible for the mechanism of drug resistance. Cytogenet Cell Genet 2001;95:34-42.